TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03606551

Intervention type: DEVICE
Intervention: EXD-959 Bracket System
Description: EXD-959 Ceramic Self-ligating Brackets are a new type of esthetic ceramic bracket developed by 3M™ Oral Care Solutions. The brackets have a sliding door and are composed of alumina (aluminum oxide) and small amounts of related oxide compounds (glass powder) to give them a clear appearance. A nickel-titanium wire serves as part of the door mechanism and is attached to the bracket using 3M ESPE™ Scotchbond™ Universal Adhesive. The brackets are classified as a Class II medical device. A FDA 510(k) submission of EXD-959 was submitted the first quarter of 2018.

Intervention type: DEVICE
Intervention: EXD-959 Bracket System
Description: EXD-959 Ceramic Self-ligating Brackets are a new type of esthetic ceramic bracket developed by 3M™ Oral Care Solutions. The brackets have a sliding door and are composed of alumina (aluminum oxide) and small amounts of related oxide compounds (glass powder) to give them a clear appearance. A nickel-titanium wire serves as part of the door mechanism and is attached to the bracket using 3M ESPE™ Scotchbond™ Universal Adhesive. The brackets are classified as a Class II medical device. A FDA 510(k) submission of EXD-959 was submitted the first quarter of 2018.

Intervention type: DEVICE
Intervention: EXD-959 Bracket System
Description: EXD-959 Ceramic Self-ligating Brackets are a new type of esthetic ceramic bracket developed by 3M™ Oral Care Solutions. The brackets have a sliding door and are composed of alumina (aluminum oxide) and small amounts of related oxide compounds (glass powder) to give them a clear appearance. A nickel-titanium wire serves as part of the door mechanism and is attached to the bracket using 3M ESPE™ Scotchbond™ Universal Adhesive. The brackets are classified as a Class II medical device. A FDA 510(k) submission of EXD-959 was submitted the first quarter of 2018.
Study: NCT00759954

Intervention type: DRUG
Group type: OTHER
Intervention: KADIAN (morphine sulfate sustained-release) capsules
Description: 2 x 100 mg, single-dose capsule

Intervention type: DRUG
Group type: OTHER
Intervention: KADIAN (morphine sulfate sustained-release) capsules
Description: 2 x 100 mg, single-dose capsule
Study: NCT02368431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zonisamide
Description: Titration of dose to 500mg oral, daily, over 8 weeks, then 7 weeks of treatment at that dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00526994

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: screened
Description: Asked 4 questions on current exposure to intimate partner violence; if positive, receives referral information
Study: NCT04182321

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo & Entecavir
Description: Adding placebo (oral, once a day) for 24 weeks to the ongoing entecavir therapy (0.5 mg, oral, once a day)
Study: NCT01698450

Intervention type: DEVICE
Group type: OTHER
Intervention: Non-invasive intervention with focused ultrasound (ExAblate 4000)
Description: Non-invasive brain intervention using MR-guided focused ultrasound
Study: NCT03384563

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine 9 arms

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine 9 arms

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine 9 arms

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine 9 arms

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine 9 arms

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine 9 arms

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine 9 arms

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine 9 arms

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine 9 arms
Study: NCT00387179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: 5mg, pill, once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: 5mg, pill, once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylxanthine
Description: 2.9 mg/kg, pill, once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylxanthine
Description: 2.9 mg/kg, pill, once

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Light Therapy
Description: Bright light exposure

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Light Therapy
Description: Bright light exposure
Study: NCT01551290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: Form = solution for injection, route = intravenous (IV), Unit = mg/kg, number = 5, administered on = Weeks 0, 2, 6, 14, and 22 and for extension phase: participants treated with infliximab through Week 22 will receive infliximab at Weeks 30, 38, 46 and 54, and will receive placebo at Week 32 and 34.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Form = solution for injection, route = IV, administered on = Weeks 0, 2, 6, 14, and 22 and for extension phase: participants treated with placebo through Week 22 will receive infliximab at Weeks 32, 34, 38, 46 and 54 and will receive placebo at Week 30.
Study: NCT02141490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferumoxytol
Description: 7.5mg/kg intravenous (IV) infusion

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Description: 3 MRIs: pre-infusion, 24 and 48 hours post-infusion
Study: NCT01550341

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine/naloxone
Description: 2/0.5, 8/2 sublingual tabs; dosage based on medical assessment; medications taken once per day for 12 months duration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: 2/0.5, 8/2 sublingual tabs; dosage based on medical assessment; medications taken once per day for 12 months duration.
Study: NCT01213186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: high dose of MSC
Description: Taken i.v., at week 0, 4, 12, 24, 36 and 48, at a dose of 1.5\*10E6/kg for 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low dose of MSC treatment
Description: Taken i.v., at week 0, 4, 12, 24, 36 and 48, at a dose of 0.5\*10E6/kg for 48 weeks.
Study: NCT02451683

Intervention type: OTHER
Group type: OTHER
Intervention: Electrophysiology Assessment of Time Domain
Description: Kinematics, Spinal Cord Excitability and Cortical Spinal Motor Excitability.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electrophysiology Assessment of Location
Description: Kinematics, Spinal Cord Excitability and Cortical Spinal Motor Excitability

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training with some stimulation
Description: motor task combined with real or sham stimulation

Intervention type: OTHER
Group type: OTHER
Intervention: Training with some stimulation
Description: motor task combined with real or sham stimulation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Training with some stimulation
Description: motor task combined with real or sham stimulation
Study: NCT04038892

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Chest Physiotherapy
Description: Programme will include diaphragmatic breathing exercise, thoracic expansion exercises, incentive spirometer exercise (Triflo), oscillatory PEP (Flutter), postural drainage, coughing techniques and teaching respiratory control.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Chest Physiotherapy
Description: Programme will include diaphragmatic breathing exercise, thoracic expansion exercises, incentive spirometer exercise (Triflo), oscillatory PEP (Flutter), postural drainage, coughing techniques and teaching respiratory control.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Chest Physiotherapy
Description: Programme will include diaphragmatic breathing exercise, thoracic expansion exercises, incentive spirometer exercise (Triflo), oscillatory PEP (Flutter), postural drainage, coughing techniques and teaching respiratory control.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nintendo Wii Fit Based Exercise Training
Description: Nintendo Wii Fit based exercise training will be given under the supervision of a physiotherapist. The one session will be included: warm-up exercises for 5 minutes (yoga games; deep breathing and half moon etc.), aerobic exercises for 30 minutes (aerobic games; Twisting and Squat, Step Plus, Jogging Plus and Hula Hoop etc.) and cooling exercises in 5 minutes (yoga games; deep breathing and half moon etc.).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BreathingLabs Breathing Games Based Exercise Training
Description: BreathingLabs Breathing Games based exercise training will be given under the supervision of a physiotherapist. The one session will be included: warm-up exercises for 5 minutes (respiratory control exerice and coughing techniques), breathing games exercises for 30 minutes (breathing games; Kite, Balloon, Pluto, Butterflies and Plane etc.) and cooling exercises in 5 minutes (respiratory control exerice and coughing techniques).
Study: NCT04531358

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nasal spray
Description: application of nasal spray

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nasal spray
Description: application of nasal spray

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: no treatment
Description: no treatment
Study: NCT01884558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isavuconazole
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: oral
Study: NCT00011414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tariquidar
Description: IV alone for 1 dose (Day -1), then in combo for rest of cycle (Day 1, etc). Given in combo with one of the following: Doxorubicin (50 mg/m2 IV over 15 min on day 1), Vinorelbine (20 mg/m2 IV over 10 min on days 1 and 8), or Docetaxel (75 mg/m2 IV over 60 min on day 1).
Study: NCT01241344

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brincidofovir
Description: * Adult subjects: 200mg BCV administered as 50mg tablets taken orally either once weekly (QW; 4 tablets) or twice weekly (BIW; 2 tablets).~* Pediatric subjects: 4mg/kg BCV (not to exceed a total single dose of 200mg) administered using a 10 mg/mL liquid formulation taken orally either QW (as 4 mg/kg) or BIW (as 2 mg/kg).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Adult subjects: Matching placebo tablets taken orally either once weekly (QW; 4 tablets) or twice weekly (BIW; 2 tablets).~• Pediatric subjects: Matching liquid placebo taken orally either QW (as 4 mg/kg) or BIW (as 2 mg/kg).
Study: NCT03807297

Intervention type: DRUG
Group type: OTHER
Intervention: Injection dexmedetomidine
Description: alpha 2 a agonist used for sedation, analgesia

Intervention type: DRUG
Group type: OTHER
Intervention: Injection, Propofol, 10 Mg
Description: non barbiturate type of intravenous anaesthetic drug

Intervention type: OTHER
Group type: OTHER
Intervention: sevoflurane
Description: inhalational anaesthetic agent

Intervention type: OTHER
Group type: OTHER
Intervention: nitrous oxide
Description: inhalational anaesthetic agent
Study: NCT01960127

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Aerobic exercise

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: No Intervention
Description: No Intervention
Study: NCT02952482

Intervention type: PROCEDURE
Intervention: newborns testing for ALD
Description: Routine newborn screening dried blood spots sample is used to test if elevation of C26:0-lyso-PC
Study: NCT03426475

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: interprof ACT measures
Description: Definition of common goals between general practitioner and nursing staff, appointment of a contact person, support in assigning medication, use of name badges worn by GPs and nurses during visits, mandatory availability of contact person, standardized procedures for GPs home visits
Study: NCT02076399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib disodium
Description: Fostamatinib (100 mg PO bid or 150 mg PO bid)

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo tablet PO bid (morning and evening) over the course of 24 weeks
Study: NCT01140568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nilotinib
Description: 400mg po (orally) BID (twice daily)
Study: NCT03348956

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: EPR Oximetry
Description: Subjects will have up to five EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.
Study: NCT03852355

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency
Description: ), received bilateral 3rd occipital nerve RF under fluoroscopic guidance. Levobupivacaine (0.3 mL; 0.75%) and triamcilonone (1 mg) were injected at each level

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Steroids
Description: received systemic steroids oral prednisolone tablet, 10 mg/day
Study: NCT00596570

Intervention type: PROCEDURE
Intervention: PCI
Description: Percutaneous coronary interventiom
Study: NCT02097810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entrectinib
Study: NCT02685020

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.Mos.HIV
Description: Recombinant replication-deficient Ad26 vectored vaccine and consists of 3 Ad26 vectors, one containing a mosaic insert of envelope (Env) sequence, and 2 vectors containing mosaic inserts of Gag and Pol sequences (Ad26.Mos.1.Env + Ad26.Mos1.Gag-Pol + Ad26.Mos2.Gag-Pol). Total dose is 5\*10\^10 viral particle per 0.5 milliliter (mL) injection administered intramuscularly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.Mos.HIV
Description: Recombinant replication-deficient Ad26 vectored vaccine and consists of 3 Ad26 vectors, one containing a mosaic insert of envelope (Env) sequence, and 2 vectors containing mosaic inserts of Gag and Pol sequences (Ad26.Mos.1.Env + Ad26.Mos1.Gag-Pol + Ad26.Mos2.Gag-Pol). Total dose is 5\*10\^10 viral particle per 0.5 milliliter (mL) injection administered intramuscularly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.Mos.HIV
Description: Recombinant replication-deficient Ad26 vectored vaccine and consists of 3 Ad26 vectors, one containing a mosaic insert of envelope (Env) sequence, and 2 vectors containing mosaic inserts of Gag and Pol sequences (Ad26.Mos.1.Env + Ad26.Mos1.Gag-Pol + Ad26.Mos2.Gag-Pol). Total dose is 5\*10\^10 viral particle per 0.5 milliliter (mL) injection administered intramuscularly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Clade C gp140
Description: The Clade C gp140 vaccine containing 250 mcg of total protein, mixed with aluminum phosphate adjuvant, per 0.5 mL injection administered intramuscularly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Clade C gp140
Description: The Clade C gp140 vaccine containing 250 mcg of total protein, mixed with aluminum phosphate adjuvant, per 0.5 mL injection administered intramuscularly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Clade C gp140
Description: The Clade C gp140 vaccine containing 250 mcg of total protein, mixed with aluminum phosphate adjuvant, per 0.5 mL injection administered intramuscularly.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline, 0.5 mL injection administered intramuscularly.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline, 0.5 mL injection administered intramuscularly.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline, 0.5 mL injection administered intramuscularly.
Study: NCT02186912

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nobel Active, Nobel Procera IBO

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nobel Active, Nobel Procera IBO
Study: NCT01037647

Intervention type: OTHER
Intervention: Hyperinsulinemic euglycemic glucose clamp
Description: Hyperinsulinemic euglycemic glucose clamp, duration 5 hours, plasma glucose 5 mmol/l, insulin dosage 1,0 mU•kg FFM/min, human insulin (Actrapid; Novo Nordisk A/S).

Intervention type: OTHER
Intervention: Hyperinsulinemic euglycemic glucose clamp
Description: Hyperinsulinemic euglycemic glucose clamp, duration 5 hours, plasma glucose 5 mmol/l, insulin dosage 1,0 mU•kg FFM/min, human insulin (Actrapid; Novo Nordisk A/S).
Study: NCT01220947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copegus
Description: Copegus 1000 mg or 1200 mg po daily for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copegus
Description: Copegus 1000 mg or 1200 mg po daily for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copegus
Description: Copegus 1000 mg or 1200 mg po daily for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copegus
Description: Copegus 1000 mg or 1200 mg po daily for 24 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Copegus
Description: Copegus 1000 mg or 1200 mg po daily for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danoprevir
Description: Danoprevir 50 mg BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danoprevir
Description: Danoprevir 100 mg BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danoprevir
Description: Danoprevir 100 mg BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danoprevir
Description: Danoprevir 200 mg BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegasys
Description: Pegasys 180 microgram sc qw

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegasys
Description: Pegasys 180 microgram sc qw

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegasys
Description: Pegasys 180 microgram sc qw

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegasys
Description: Pegasys 180 microgram sc qw

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegasys
Description: Pegasys 180 microgram sc qw

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Ritonavir 100 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Ritonavir 100 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Ritonavir 100 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Ritonavir 100 mg
Study: NCT03012958

Intervention type: OTHER
Intervention: Lung clearance index (LCI)
Description: LCI is determined by the number of lung volume turnovers necessary to clear the lungs of an inert tracer gas such as nitrogen that is inhaled at the beginning of the test. The LCI is calculated by determining the cumulative expired volume (CEV) and then dividing the CEV by the functional residual capacity. Values of less than7.0 indicate normal values while an LCI greater than 7.0 is associated with heterogeneity in ventilation and distal airway abnormalities. The ability to detect peripheral airway disease may make LCI a better modality for detecting distal airways abnormalities seen on lung histopathology but often missed on traditional pulmonary function testing.

Intervention type: OTHER
Intervention: Lung clearance index (LCI)
Description: LCI is determined by the number of lung volume turnovers necessary to clear the lungs of an inert tracer gas such as nitrogen that is inhaled at the beginning of the test. The LCI is calculated by determining the cumulative expired volume (CEV) and then dividing the CEV by the functional residual capacity. Values of less than7.0 indicate normal values while an LCI greater than 7.0 is associated with heterogeneity in ventilation and distal airway abnormalities. The ability to detect peripheral airway disease may make LCI a better modality for detecting distal airways abnormalities seen on lung histopathology but often missed on traditional pulmonary function testing.
Study: NCT01288248

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Airway laryngeal mask classic
Description: This group includes patients with the randomization process are assigned to use Classic laryngeal mask as a method to secure the airway after induction of anesthesia, which will be maintained during surgery and removed the patient asleep once you are done the surgical procedure to determine the presence or absence of laryngospasm.~The laryngeal mask mark to be used will laryngeal Mask Device ® which comes in different sizes and sterilized in ethylene oxide. The size of the Classic laryngeal mask is used according to the weight assigned

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: endotracheal tube
Description: This group includes patients with the randomization process are allocated to use endotracheal tube method for securing the airway after induction of anesthesia, which will be maintained during surgery and removed in the awake patient when you finish the surgical procedure to determine the presence or absence of laryngospasm.~The marks of the endotracheal tube will be one of the following: Kendall Curity ®, Well Lead Medical ®, Meditec ®, which are not reusable. The size of the endotracheal tube be allocated according to age.
Study: NCT02536352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prenatal vitamin-mineral containing 3 mg fluoride
Description: Prenatal vitamin-mineral containing 3 mg fluoride to be taken daily, starting at 10-20 weeks gestation until delivery.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Prenatal vitamin-mineral containing 0 mg fluoride
Description: Prenatal vitamin-mineral containing 0 mg fluoride to be taken daily, starting at 10-20 weeks gestation until delivery.
Study: NCT03869866

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid conjugate vaccine MenACYW conjugate vaccine
Description: Pharmaceutical form: Solution for injection Route of administration: Intramuscular
Study: NCT00493636

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine will be administered 1000 mg/m2 pm Days 1 and 8 of a 21 day cycle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine will be administered 1000 mg/m2 pm Days 1 and 8 of a 21 day cycle
Study: NCT00526994

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: universal education
Description: receives referral information